Skip to main content
Premium Trial:

Request an Annual Quote

23andMe on the Nasdaq

In its first day of trading, 23andMe's shares rose more than 20 percent, as GenomeWeb reports.

23andMe merged with special purpose acquisition company VG Acquisition Corp., sponsored by Richard Branson's Virgin Group, to become a publicly traded entity on the Nasdaq with the ticker symbol ME, it adds. When the deal was announced in February, 23andMe said its enterprise value was about $3.5 billion.

Fortune notes that 23andMe co-founder and CEO Anne Wojcicki had long been wary of taking the firm public, but now says the pandemic further piqued people's interest in genomics and sequencing as well as in healthcare more generally, changing her mind. Additionally, the SPAC merger approach allowed 23andMe to go public while avoiding the uncertainty of an initial public offering, Fortune says.

According to Yahoo Finance, shares of 23andMe rose 21 percent to close Thursday at $13.32. GenomeWeb adds that the company said it raised about $592 million in gross proceeds, which it is to use to expand its consumer health and therapeutics businesses as well as to develop its genetic and phenotypic databases.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.